EXINI Diagnostics AB
EXINI´s imaging biomarker BSI to be presented at ASCO
DGAP-News: EXINI Diagnostics AB 2015-05-19 / 08:29 --------------------------------------------------------------------- Lund, Sweden, 2015-05-19 08:29 CEST (GLOBE NEWSWIRE) -- A new important BSI-study is to be presented at the 2015 ASCO-congress (American Society of Clinical Oncology) held in Chicago, USA. The congress, which is the world's largest in oncology, gathers approximately 30 000 oncology-experts from all over the World. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and on-going controversies in the field. Science sessions present the latest important research in oral or poster format. 'The BSI-study is one out of merely three biomarker studies accepted for presentation at this year's ASCO-congress. Getting the approval from the world's largest and highest ranked congress in oncology serves as further proof of the growing interest in BSI within the oncology community,' comments Magnus Aurell, CEO, EXINI Diagnostics AB. Details on the BSI-presentation: 'Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer' authored by Aseem Anand et al, Lund University (Lund, Sweden). The presentation abstract is available at: http://abstracts.asco.org/156/AbstView_156_149539.html More on Bone Scan Index (BSI): BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate cancer. Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI boneBSI is the only software capable of calculating the BSI-value. www.bonescanindex.org www.exini.com/software/exini-bone-bsi/ For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North and has about 1000 shareholders. Consensus acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-05-19 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden ISIN: SE0001810284 End of News DGAP News-Service --------------------------------------------------------------------- 359045 2015-05-19
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden